Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 October 2019
Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (TA308)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 March 2014
Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (TA223)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 May 2011
Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin (TA159)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 October 2008
Semaglutide for treating type 2 diabetes and associated peripheral arterial disease TS ID 11791Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC